Memantine in moderate to severe Alzheimer's disease: an observational post-marketing study (Q51014247)

27 March 2018

title

Memantine in moderate to severe Alzheimer's disease: an observational post-marketing study (English)

1 reference

27 March 2018

1 reference

Michael Rainer

1

1 reference

27 March 2018

A Wuschitz

2

1 reference

27 March 2018

C Jagsch

3

1 reference

27 March 2018

C Erb

4

1 reference

27 March 2018

J-J Chirikdjian

5

1 reference

27 March 2018

H A M Mucke

6

1 reference

27 March 2018

publication date

2 April 2011

1 reference

27 March 2018

Journal of Neural Transmission

published in

1 reference

27 March 2018

volume

118

1 reference

27 March 2018

issue

8

1 reference

27 March 2018

page(s)

1255-1259

1 reference

27 March 2018

Long-term course and effectiveness of combination therapy in Alzheimer disease

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0623-8

Memantine (Ebixa) in clinical practice - results of an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0623-8

Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0623-8

Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0623-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0623-8

Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0623-8

Alzheimer's disease in real life--the dementia carer's survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0623-8

Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0623-8

Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0623-8

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0623-8

Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0623-8

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0623-8

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0623-8

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0623-8

A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0623-8

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0623-8

A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0623-8

Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0623-8

Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0623-8

Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21461744

12 December 2020

inferred from PubMed ID database lookup

Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21461744

12 December 2020

inferred from PubMed ID database lookup

Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21461744

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S00702-011-0623-8

1 reference

27 March 2018

release_7etru247p5cb7ftmhn7fnqwweu

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7etru247p5cb7ftmhn7fnqwweu

24 November 2022

mapped directly with Wikidata item

1 reference

27 March 2018